To cite this paper use one of the standards below:
Dermatomyositis (DM) is a subclassification of idiopathic inflammatory myopathy, characterized by progressive muscle atrophy and degeneration, accompanied by extramuscular symptoms such as bluish-purple skin lesions. The enzyme Indoleamine 2,3-Dioxygenase 1 (IDO1) is described in the literature as promoting immune tolerance, mediated by the depletion of Tryptophan (Trp) and the synthesis of Kynurenine (Kyn), generating a cascade of metabolites with bioactive functions that modulate the immune response. This study aims to investigate the expression and functional role of IDO1 in skeletal muscle cells and its possible function in inflammatory conditions associated with Dermatomyositis. To this end, immortalized skeletal muscle cells (CL48) were cultured and divided into four experimental groups: the control group, stimulated with LPS, treated with the IDO1 inhibitor (MDT) and/or 1-methyltryptophan (1-MT), and a combined MDT/1-MT with LPS group. Additional pro-inflammatory cytokines as stimuli were also incubated with the inhibitors to assess responses in myoblasts. Initial results suggest a reduction in cell viability with higher doses of MDT, as well as a reduction in cell proliferation when inflammatory stimuli are incubated with the inhibitors. Preliminary assays indicated a reduction in cell viability associated with the increase in IDO1 inhibitor concentration in proliferating skeletal muscle cells. Preliminary assays evaluating cell proliferation and viability showed reduced cytokine levels when MDT/1-MT was combined with LPS or other inflammatory cytokines, compared to the group stimulated with LPS alone. The initial results suggest that IDO1 plays a significant role in modulating inflammation, possibly preventing exacerbated inflammation in skeletal muscle tissue. These findings indicate a potential relevance of IDO1 in the pathophysiology of dermatomyositis and open new perspectives for targeted therapies for myopathies.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper